[1]Li H，Zhang KH，Yang JH，et al.Research progress of thyroid cancer markers［J］.Translational Medicine E-Journal，2018，5(01)：57-62.［李贺，张凯华，杨家慧，等.甲状腺癌标志物的研究进展［J］.转化医学电子杂志，2018，5(01)：57-62.］
[2]Lu JY，Cheng WC，Chen KY，et al.Using Ion torrent sequencing to study genetic mutation profiles of fatal thyroid cancers［J］.Journal of the Formosan Medical Association，2018，117(6)：488-496．
[3]Ren H，Shen Y，Hu D，et al.Co-existence of BRAF(V600E) and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness，but not with lymph node metastasis［J］.Cancer Manag Res，2018，10：1005-1013.
[4]Fernandez-Ramirez F，Hurtado-Lopez LM，Lopez MA，et al.BRAF 1799＞A mutation frequency in mexican mestizo patients with papillary thyroid cancer［J］.Biomed Res Int，2018，2(4)：2582179.
[5]Arcolia V，Journe F，Renaud F，et al.Combination of galectin-3，CK19 and HBME-1 immunostaining improves the diagnosis of thyroid cancer［J］.Oncol Lett，2017，14(4)：4183-4189.
[6]Li Y，Zhang Y，Xiao S，et al.Mps1 is associated with the BRAF(V600E) mutation but does not rely on the classic RAS/RAF/MEK/ERK signaling pathway in thyroid carcinoma［J］.Oncol Lett，2018，15(6)：9978-9986.
[7]Insilla AC，Proietti A，Borrelli N，et al.TERT promoter mutations and their correlation with BRAF and RAS mutations in a consecutive cohort of 145 thyroid cancer cases［J］.Oncology Letters，2018，15(3)：2763-2770.
[8]Bellevicine C，Sgariglia R，Migliatico I，et al.Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF，RAS，RET/PTC，and PAX8/PPARg alterations［J］.Cancer Cytopathol，2018，126(5)：317-325.
[9]Mei ZD，Chen C，Hu ZW，et al.Progress in the research of molecular markers for the diagnosis and prognosis of thyroid cancer［J］.Modern Biomedical Advances，2017，17(18)：3592-3595.［梅志丹，陈晨，胡章威，等.甲状腺癌诊断及预后相关分子标志物的研究进展［J］.现代生物医学进展，2017，17(18)：3592-3595.］
[10]Zarkesh M，Zadeh-Vakili A，Azizi F，et al.The Association of BRAF V600E mutation with tissue inhibitor of metalloproteinase-3 expression and clinicopathological features in papillary thyroid cancer［J］.Int J Endocrinol Metab，2018，16(2)：e56120.
[11]Ko YS，Hwang TS，Kim JY，et al.Diagnostic limitation of fine-needle aspiration（FNA) on indeterminate thyroid nodules can be partially overcome by preoperative molecular analysis：Assessment of RET/PTC1 rrearrangement in BRAF and RAS wild-type routine air-dried FNA specimens［J］.Int J Mol Sci，2017，18(4)：806.
[12]Xuan Su，Caiyun He，Jiangjun Ma，et al.RET/PTC rearrangements are associated with elevated postoperative TSH levels and multifocal lesions in papillary thyroid cancer without concomitant thyroid benign disease［J］.PLoS One，2016,11(11)：e0165596.
[13]Hao Z，Cui JY.Progress in molecular biology of differentiated thyroid cancer［J］.Chinese Contemporary Medicine，2013，20(26)：19-20,22.［郝智，崔建英.分化型甲状腺癌分子生物学的研究进展［J］.中国当代医药，2013，20(26)：19-20,22.］
[14]Romei C，Ciampi R，Casella F，et al.RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases［J］.Oncotarget，2018，9(11):9875-9884.
[15]Paulson VA，Shivdasani P，Angell TE，et al.Noninvasive follicular thyroid neoplasm with papillary-like nuclear features accounts for more than half of "Carcinomas" harboring RAS mutations［J］.Thyroid，2017，27，(4)：506-511.
[16]Mehrzad R，Nishino M，Nucera C，et al.Invasive follicular variant of papillary thyroid cancer harboring the NRAS mutation Q61K and presenting with bone metastasis-A case report［J］.Int J Surg Case Rep，2017，38：180-184.
[17]Cavedon E，Barollo S，Bertazza L，et al.Prognostic impact of miR-224 and RAS mutations in medullary thyroid carcinoma［J］.Int J Endocrinol，2017，2017：4915736.
[18]Myriem Boufraqech，Joanna Klubo-Gwiezdzinska，Kebebew E.MicroRNAs in the thyroid［J］.Best Pract Res Clin Endocrinol Metab，2016，30(5)：603-619.
[19]Liang L.Talking about the relationship between microRNA and thyroid cancer［J］.The Latest Medical Information Digest in the World，2017，17(80)：150,152.［梁良.microRNA与甲状腺癌的关系［J］.世界最新医学信息文摘，2017，17(80)：150,152.］
[20]Huo MR，Liu X.Progress in molecular diagnostic markers of thyroid cancer［J］.Medicine and Philosophy（B)，2017，38(06)：67-71.
[21]Saiselet M，Pita JM，Augenlicht A，et al.miRNA expression and function in thyroid carcinomas：A comparative and critical analysis and a model for other cancers［J］.Oncotarget，2016，7(32)：52475-52492.
[22]Lopez-Santillan M，Larrabeiti-Etxebarria A，Arzuaga-Mendez J，et al.Circulating miRNAs as biomarkers in diffuse large B-cell lymphoma：A systematic review［J］.Oncotarget，2018，9(32)：22850-22861.
[23]Wu XJ，Zhang YX.MicroRNA and ultrasound elastography in diagnosis of thyroid cancer［J］.Journal of Inner Mongolia Medical University，2016，38(03)：239-245.
[24]Qiu J，Sun Y.Significance of detection of tumor markers in the diagnosis and treatment of thyroid cancer［J］.Journal of Otolaryngology and Ophthalmology of Shandong University，2016，30(02)：28-31.［邱杰，孙彦.肿瘤标志物检测在甲状腺癌临床诊治中的意义［J］.山东大学耳鼻喉眼学报，2016，30(02)：28-31.］
[25]Abu-Sinna E，Hasan MY，El-Deftar MM，et al.Galectin-3 and HBME-1 expression on agarose cell blocks from fine-needle aspirates of follicular cell-derived thyroid tumors［J］.J Cytol，2018，35(1)：27-32.
[26]Zheng J，Lu W，Wang C，et al.Galectin-3 induced by hypoxia promotes cell migration in thyroid cancer cells［J］.Oncotarget，2017，8(60)：101475-101488.
[27]Trimboli P，Virili C，Romanelli F，et al.Galectin-3 performance in histologic a cytologic assessment of thyroid nodules：A systematic review and Meta-analysis［J］.Int J Mol Sci，2017，18(8)：1756.
[28]Sciacchitano S，Lavra L，Morgante A，et al.Galectin-3：One molecule for an alphabet of diseases，from A to Z［J］.Int J Mol Sci，2018，19(2)：379.
[29]T Takano，A Miyauchi，H Yoshida，et al.High-throughput differential screening of mRNAs by serial analysis of gene expression：Decreased expression of trefoil factor 3 mRNA in thyroid follicular carcinomas［J］.British Journal of Cancer，2004，90(8)：1600-1605.
[30]Taniguchi K，Takano T，Miyauchi A，et al.Differentiation of follicular thyroid adenoma from carcinoma by means of gene expression profiling with adapter-tagged competitive polymerase chain reaction［J］.Oncology，2005，69(5)：428-435.
[31]Wang WJ，Zheng F.Clinical significance of TFF-3 and galectin-3 in differential diagnosis of thyroid tumors［J］.Journal of Tongji University（Medical Science)，2016，37(06)：115-119.［王维健，政峰.TFF-3和半乳糖凝集素-3在甲状腺肿瘤鉴别诊断中的临床意义［J］.同济大学学报(医学版)，2016，37(06)：115-119.］
[32]Palo S，Biligi DS.Differential diagnostic significance of HBME-1，CK19 and S100 in various thyroid lesions［J］.Malays J Pathol，2017，39(1)：55-67.
[33]Hatice Toy，Ozlem Etli，Zeliha Esin Celik，et al.Associations between nucleus size，and immunohistochemical Galectin-3，Cytokeratine-19 and HBME-1 markers in thyroid papillary carcinoma：A morphometric analyze［J］.Pathol Oncol Res，2017，12(4)：1-8.
[34]Mu WN，Qiang Y，Liu YT.Progress in clinical application of thyroid cancer molecular markers［J］.Shandong Pharmaceutical，2016，56(14)：102-104.
[35]Liu H，Liu Q，Ge Y，et al.hTERT promotes cell adhesion and migration independent of telomerase activity［J］.Sci Rep，2016，6：22886.
[36]Sayiner A，Suren D.Expression of human telomerase reverse transcriptase（hTERT) in thyroid neoplasms［J］.J BUON，2018，23(1)：229-233.